Equities research analysts expect Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report ($2.06) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Orexigen Therapeutics’ earnings. Orexigen Therapeutics posted earnings of ($2.67) per share during the same quarter last year, which would indicate a positive year over year growth rate of 22.8%. The firm is scheduled to issue its next earnings results on Tuesday, March 27th.
On average, analysts expect that Orexigen Therapeutics will report full year earnings of ($10.08) per share for the current year. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Orexigen Therapeutics.
Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.78. The business had revenue of $18.90 million during the quarter, compared to analysts’ expectations of $24.20 million. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 192.65%. The firm’s revenue for the quarter was up 170.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.12 earnings per share.
An institutional investor recently raised its position in Orexigen Therapeutics stock. Wells Fargo & Company MN grew its position in Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 45,638 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the period. Wells Fargo & Company MN owned 0.30% of Orexigen Therapeutics worth $132,000 as of its most recent filing with the SEC. 34.57% of the stock is owned by institutional investors.
Shares of Orexigen Therapeutics (OREX) traded down $0.03 during mid-day trading on Monday, hitting $1.10. The company had a trading volume of 467,969 shares, compared to its average volume of 269,956. The company has a current ratio of 2.00, a quick ratio of 1.71 and a debt-to-equity ratio of -2.75. The company has a market capitalization of $18.76, a PE ratio of -0.11 and a beta of 2.31. Orexigen Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.70.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/29/2-06-earnings-per-share-expected-for-orexigen-therapeutics-inc-orex-this-quarter.html.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.